---
title: Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
date: '2024-06-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38912654/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240624182223&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: Among persons with moderate-to-severe obstructive sleep
  apnea and obesity, tirzepatide reduced the AHI, body weight, hypoxic burden, hsCRP
  concentration, and systolic blood pressure and improved sleep-related patient-reported
  outcomes. (Funded by Eli Lilly; SURMOUNT-OSA ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: Among persons with moderate-to-severe obstructive sleep apnea and obesity, tirzepatide reduced the AHI, body weight, hypoxic burden, hsCRP concentration, and systolic blood pressure and improved sleep-related patient-reported outcomes. (Funded by Eli Lilly; SURMOUNT-OSA ClinicalTrials.gov number, ...